Compugen: First Quarter Financial Results, Accomplishments and Future Plans

Compugen Updated Trial Data 

  • Updated data from COM701 Phase 1 combination and monotherapy studies to be presented at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
  • Milestone rich 2021 to include data readouts from ongoing COM701 triple combination study and COM902 monotherapy study in Q4 2021
  • Initiation of Phase 1b cohort expansion study of COM701 with Opdivo® in Q2 2021 and Phase 1 COM701 with COM902 dual combination study in 2H 2021 will expand systematic DNAM axis clinical evaluation

From the President & CEO of Compugen 
Compugen . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.